All In Biotech

Drug Trial Radar · NCT03708965

An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

19

Actual

Start

Jan 1, 2019

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
JCR Pharmaceuticals Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 0 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase II open-label, parallel group, 2 sites (Brazil), designed to evaluate the long term safety and efficacy of study drug for the treatment of the MPS II.

Conditions

  • Mucopolysaccharidosis II

Interventions

  • JR-141Drug

    IV infusion (lyophilized powder)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse EventsTime frame: From screening up to the end of study, up to approximately 5 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Grupo de Pesquisa Clínica em Genética Médica - HCPA

    Porto Alegre, Brazil

  • Igeim - Unifesp

    São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.